In Critical Path Update, Novartis Official Says Industry Should Pool Available Biomarker Data | GenomeWeb

A Novartis Pharmaceuticals official advocated sharing biomarker data among industry in a US Food and Drug Administration webcast discussing the agency’s “Critical Path” initiative.

Providing that pharma can protect its intellectual property, it would be advantageous for industry to pool biomarker data, Mathias Hukkelhoven, senior vice president and global head of drug regulatory affairs of Basel, Switzerland-based Novartis, said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.